Buccal administration refers to a enteral route of administration by which drugs diffuse through the oral mucosa (tissues which line the mouth) and enter directly into the bloodstream. Buccal administration may provide better bioavailability of some drugs and a more rapid onset of action compared to oral administration because the medication does not pass through the digestive system and thereby avoids first pass metabolism.
As of May 2014, buccal forms of the psychiatric drug, asenapine; the opioid drugs buprenorphine, naloxone, and fentanyl; the cardiovascular drug nitroglycerin; the nausea medication Prochlorperazine; the hormone replacement therapy testosterone, and nicotine as a smoking cessation aid, were commercially available in buccal forms, as was midazolam, an anticonvulsant, used to treat acute epileptic seizures.
Buccal administration of vaccines has been studied, but there are challenges to this approach due to immune tolerance mechanisms that prevent the body from over-reacting to immunogens encountered in the course of daily life.
- Sattar, M; Sayed, OM; Lane, ME (Aug 2014). "Oral transmucosal drug delivery--current status and future prospects". Int J Pharm 471 (1-2): 498–506. PMID 24879936. doi:10.1016/j.ijpharm.2014.05.043.
- Brigo, F et al. (2015). "Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: A systematic review with meta-analysis". Epilepsy Behav 55: 555. PMID 25817929. doi:10.1016/j.yebeh.2015.02.030.
- Kraan, H et al. (Sep 2014). "Buccal and sublingual vaccine delivery". J Control Release 190: 580–92. PMID 24911355. doi:10.1016/j.jconrel.2014.05.060.